These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28043153)

  • 1. Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials.
    Mencoboni M; Filiberti RA; Taveggia P; Bruzzone A; Garuti A; Del Corso L; Ginocchio E; Brianti A; Simonassi C; Zucali P
    Neoplasma; 2017; 64(2):253-261. PubMed ID: 28043153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
    Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
    Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
    Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
    Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
    Akazawa Y; Igawa S; Yamada K; Yamamoto H; Yagami Y; Kaizuka N; Manaka H; Kasajima M; Nakahara Y; Sato T; Mitsufuji H; Yokoba M; Kubota M; Sasaki J; Naoki K
    Oncology; 2023; 101(11):685-694. PubMed ID: 37166346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
    Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
    Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
    Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
    Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
    Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
    Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
    Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Li M; Xie C
    Lung Cancer; 2022 Oct; 172():86-93. PubMed ID: 36027855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
    Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.